Leap Therapeutics, Inc. announced the expansion of its leadership team with the appointment of Jason S. Baum, Ph.D., as Vice President, Head of Translational Medicine and Christine M. Granfield as Vice President, Head of Regulatory Affairs and Quality. Dr. Baum joins Leap with more than a dozen years of industry experience. Most recently, he served as Executive Director and Precision Medicine Leader, General Medicine and Lung Cancer with Novartis Oncology Precision Medicine. Ms. Granfield joins Leap with more than 25 years of industry experience. Prior to joining Leap, she served as an independent regulatory consultant with Granfield Associates LLC. Previously, she was Senior Director, Regulatory Affairs with Novartis Corporation Oncology Business Unit, where she led the development of regulatory strategy and submissions for companion diagnostics supporting various oncology personalized medicine programs.
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.